Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 13/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29816208 | 0.73 | TDP1 (0.68) | KDM4EKMT2AMEN1TDP1POLB | |
| SCHEMBL13889089 | 0.71 | POLB (0.54) | LMNAKMT2AMEN1TDP1POLB | |
| SCHEMBL1809205 | 0.69 | POLB (0.51) | KMT2AMEN1TDP1POLBMAPK1 | |
| SCHEMBL14531958 | 0.69 | ALDH1A1 (0.58) | ALDH1A1LMNAGAAKDM4ERXFP1 | |
| SCHEMBL14501005 | 0.68 | ALDH1A1 (0.56) | ALDH1A1LMNAGAAKDM4ERXFP1 | |
| SCHEMBL5256458 | 0.68 | POLB (0.55) | ALDH1A1LMNAGAAKDM4ERXFP1 | |
| SCHEMBL31238166 | 0.66 | ALDH1A1 (0.70) | ALDH1A1LMNAGAAKDM4EKMT2A | |
| SCHEMBL23052529 | 0.66 | ALDH1A1 (0.67) | ALDH1A1LMNAGAAKMT2AMEN1 | |
| SCHEMBL13796886 | 0.65 | NPY5R (0.52) | ALDH1A1KMT2AMEN1TDP1HPGD | |
| SCHEMBL25202837 | 0.65 | ALDH1A1 (0.65) | ALDH1A1LMNAGAAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12419888-B2 | Methods of treating elevated plasma cholesterol | INSTITUT DE CARDIOLOGIE DE MONTREAL (CA) | 2025-09-23 | — | — | US | disclosed |
| US-20220296593-A1 | METHODS OF TREATING ELEVATED PLASMA CHOLESTEROL | INSTITUT DE CARDIOLOGIE DE MONTREAL (CA) | 2022-09-22 | — | — | US | disclosed |
| EP-4011877-A2 | METHOD OF TREATING ELEVATED PLASMA CHOLESTEROL | Institut de Cardiologie de Montréal (CA) | 2022-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220296593-A1 | METHODS OF TREATING ELEVATED PLASMA CHOLESTEROL | PCSK9, LDLR, CETP | ALDH1A1 2768/4885LMNA 619/4885GAA 968/4885 |
| US-12419888-B2 | Methods of treating elevated plasma cholesterol | PCSK9, LDLR, CETP | ALDH1A1 3153/4885LMNA 615/4885GAA 1115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.